The deal priced at below last closing price of $18.92. Jefferies, TD Securities, Leerink, Stifel and Wedbush are acting as joint book running managers for the offering.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics announces common stock offering, no amount given
- Spyre Therapeutics announces poster presentations at UEGW 2025
- Spyre Therapeutics initiated with a Buy at Deutsche Bank
- Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
- Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial